After the upward revision, achieving Q4 revenue of ¥1,182 million and operating profit of ¥246 million is the focus for FY2026.

For the nine months ended 30 September 2026, revenue was ¥3,618.3 million, up 110.3% year on year, operating profit was ¥644 million, up 35.7%, and ordinary profit was ¥607 million, up 23.4%. In contrast, profit attributable to owners of the parent was ¥280 million, down 11.7%. Progress against the full-year revenue forecast of ¥4,450 million was 81.3%, while progress for operating profit was 94.7%, ordinary profit 99.7% and net profit 122.0%.

Subsequently, on 14 September, the full-year forecast was raised to revenue of ¥4,800 million, operating profit of ¥890 million, ordinary profit of ¥820 million and profit attributable to owners of the parent of ¥400 million. The increases from the previous forecast were ¥350 million for revenue, ¥210 million for operating profit, ¥210 million for ordinary profit and ¥170 million for net profit. The upward revision was attributed to bulk sales of medical equipment, sales of medical information systems such as electronic medical records, and contributions from the Faskia Group.

Subtracting the nine-month cumulative results from the revised forecast leaves required Q4 revenue of ¥1,181.6 million, operating profit of ¥246 million, ordinary profit of ¥213 million and net profit of ¥120 million. Operating profit in particular had already reached 94.7% of the full-year forecast by the end of the third quarter, so the required Q4 profit is not substantial, but Q4 revenue concentration is high. Given the company’s earnings profile, which is affected by the timing of large-project revenue recognition, it will be necessary to confirm whether both revenue recognition and margins reach plan.

At the next earnings announcement, it will be important to explain, in addition to the four full-year indicators, the variances from the revised forecast by segment. As of the third quarter, orders received, order backlog, operating cash flow and cash at period-end had not been disclosed, so it has not been possible to determine whether Q4 revenue will come from already-booked orders or additional orders.